An intravenous injection of plasma-derived immunoglobulins is used for the treatment of severe infectious and autoimmune disorders. Despite of its clinical efficacy, precise mechanisms by which intravenous immunoglobulin (IVIg) suppresses proinflammatory immune response are still enigmatic. Here, we provide in vitro evidence that IVIg inhibits homeostatic proliferation of B cells accompanied by induction of their cell aggregation. The IVIg-driven suppression of B cell proliferation and induction of cell aggregation are both unaffected by treatment with a neutralizing antibody against low-affinity Fc receptors for IgG (CD16/FcγRIII and CD32/FcγRII), known cell surface ligands for IVIg. Our observations propose a new immunosuppressive action of IVIg, which directly acts on steady-state B cells to suppress their homeostatic expansion.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Akdis M, Palomares O, van de Veen W, van Splunter M, Akdis CA (2012) TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. J Allergy Clin Immunol 129:1438–1449
Amran D, Renz H, Lack G, Bradley K, Gelfand EW (1994) Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 73:180–186
Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104:10–20
Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105:19571–19578
Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14:509–515
Barahona Afonso AF, Joao CM (2016) The production processes and biological effects of intravenous immunoglobulin. Biomolecules 6:15
Basta M, Langlois PF, Marques M, Frank MM, Fries LF (1989) High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74:326–333
Bjorck P, Paulie S, Axelsson B (1992) Interleukin-4-mediated aggregation of anti-IgM-stimulated human B cells: inhibition of aggregation but enhancement of proliferation by antibodies to LFA-1. Immunology 75:122–128
Choi YS, Baumgarth N (2008) Dual role for B-1a cells in immunity to influenza virus infection. J Exp Med 205:3053–3064
Dourmishev LA, Guleva DV, Miteva LG (2016) Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses. Int J Inflamm 2016:3523057
Haji-Ghassemi O, Gagnon SML, Muller-Loennies S, Evans SV (2017) Polyspecificity of anti-lipid A antibodies and its relevance to the development of autoimmunity. Adv Exp Med Biol. 966:181–202
Hartung HP (2008) Advances in the understanding of the mechanism of action of IVIg. J Neurol 255:3–6
Issekutz AC, Rowter D, Miescher S, Kasermann F (2015) Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells. Clin Immunol 160:123–132
Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673
Kim SJ, Won JH (2012) B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy. Leuk Lymphoma 53:19–25
Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO (2007) Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 1110:426–432
Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere FM, Lazzeri C, Todi L, Visentini M (2015) Intravenous immunoglobulin and immunomodulation of B-cell—in vitro and in vivo effects. Front Immunol 6:4
Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M (1997) Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 34:719–729
Nagelkerke SQ, Kuijpers TW (2015) Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 5:674
Pedros C, Duguet F, Saoudi A, Chabod M (2016) Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. World J Gastroenterol 22:974–995
Pollreisz A, Assinger A, Hacker S, Hoetzenecker K, Schmid W, Lang G, Wolfsberger M, Steinlechner B, Bielek E, Lalla E, Klepetko W, Volf I, Ankersmit HJ (2008) Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro. Br J Dermatol 159:578–584
Ray A, Dittel BN (2017) Mechanisms of regulatory B cell function in autoimmune and inflammatory diseases beyond IL-10. J Clin Med 6:pii:E12
Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC (1994) Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 71:309–314
Seite JF, Goutsmedt C, Youinou P, Pers JO, Hillion S (2014) Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol 133:181–188
Seite JF, Guerrier T, Cornec D, Jamin C, Youinou P, Hillion S (2011) TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun 37:190–197
Sigman K, Ghibu F, Sommerville W, Toledano BJ, Bastein Y, Cameron L, Hamid QA, Mazer B (1998) Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 102:421–427
Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29:608–615
Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493
Von Behring E (1890) Untersuchungen ueber das Zustandekommen der Diphtherie-Immunität bei Thieren. Dtsch Med Wochenschr 16:1145–1148 (in Germany)
Von Behring E, Kitasato S (1890) Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 16:1113–1114 (in Germany)
Wunsch M, Hohmann C, Milles B, Rostermund C, Lehmann PV, Schroeter M, Bayas A, Ulzheimer J, Mäurer M, Ergün S, Kuerten S (2016) The correlation between the virus- and brain antigen-specific B cell response in the blood of patients with multiple sclerosis. Viruses 8:105
Yanes RE, Gustafson CE, Weyand CM, Goronzy JJ (2017) Lymphocyte generation and population homeostasis throughout life. Semin Hematol 54:33–38
Zuercher AW, Spirig R, Baz Morelli A, Kasermann F (2016) IVIG in autoimmune disease: potential next generation biologics. Autoimmun Rev 15:781–785
Conflict of interest
The authors declare that there is no conflict of interest regarding this study.
About this article
Cite this article
Hori, A., Fujimura, T. & Kawamoto, S. Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic proliferation of B cells. Cytotechnology 70, 921–927 (2018). https://doi.org/10.1007/s10616-017-0176-2
- B cells
- Homeostatic proliferation
- Intravenous immunoglobulin (IVIg)